Revenue Showdown: Amphastar Pharmaceuticals, Inc. vs Novavax, Inc.

Pharma Revenue Race: Amphastar vs. Novavax

__timestampAmphastar Pharmaceuticals, Inc.Novavax, Inc.
Wednesday, January 1, 201421046100030659000
Thursday, January 1, 201525151900036250000
Friday, January 1, 201625516500015353000
Sunday, January 1, 201724017500031176000
Monday, January 1, 201829466600034288000
Tuesday, January 1, 201932235700018662000
Wednesday, January 1, 2020349846000475598000
Friday, January 1, 20214377680001146290000
Saturday, January 1, 20224989870001598951000
Sunday, January 1, 2023644395000556382000
Loading chart...

Infusing magic into the data realm

Revenue Trends: Amphastar Pharmaceuticals vs. Novavax

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Amphastar Pharmaceuticals and Novavax have shown contrasting revenue trajectories over the past decade. From 2014 to 2023, Amphastar's revenue grew steadily, increasing by over 200%, peaking at approximately $644 million in 2023. In contrast, Novavax experienced a dramatic surge, particularly from 2020 to 2022, with revenues skyrocketing by over 3,000%, largely due to its COVID-19 vaccine efforts, reaching a high of nearly $1.6 billion in 2022.

While Amphastar's growth reflects consistent performance, Novavax's revenue highlights the impact of strategic product development in response to global health crises. As the pharmaceutical landscape continues to shift, these companies exemplify different paths to financial success, driven by innovation and market demand.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025